<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199588</url>
  </required_header>
  <id_info>
    <org_study_id>NEX-ULC-007</org_study_id>
    <nct_id>NCT01199588</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Efficacy, Safety and Tolerability of Nexagon® as a Topical Treatment for Subjects With Venous Leg Ulcers</brief_title>
  <acronym>NOVEL2</acronym>
  <official_title>A Randomized, Parallel Group, Dose-Ranging, Controlled, Multi-Center Study to Assess the Efficacy and Safety of Nexagon® in the Treatment of Subjects With a Venous Leg Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CoDa Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CoDa Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for subjects with a venous leg ulcer. The study is being done to determine if
      NEXAGON plus compression bandaging is more effective that placebo plus compression bandaging.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surface area reduction</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of complete closure</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete closure</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ulcer recurrence</measure>
    <time_frame>12 weeks post closure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Venous Leg Ulcers</condition>
  <arm_group>
    <arm_group_label>Nexagon® High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly applications of Nexagon® high dose in addition to compression dressings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexagon® Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Weekly applications of Nexagon® Vehicle in addition to compression dressings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Investigational Product</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Weekly application of compression dressings.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nexagon® Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly applications of Nexagon® low dose in addition to compression dressings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexagon® Low Dose</intervention_name>
    <description>Weekly, topical application of Nexagon® low dose used with compression dressings.</description>
    <arm_group_label>Nexagon® Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexagon® High Dose</intervention_name>
    <description>Weekly, topical application of Nexagon® high dose used with compression dressings.</description>
    <arm_group_label>Nexagon® High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexagon® Vehicle</intervention_name>
    <description>Weekly, topical application of Nexagon® Vehicle used with compression dressings.</description>
    <arm_group_label>Nexagon® Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of venous leg ulceration supported by venous duplex ultrasonography
             demonstrating venous reflux &gt; 0.5 seconds

          2. Ankle brachial index of &gt; 0.80

          3. Venous Leg Ulcer (VLU) area greater than 2 cm2 and less than 20 cm2

          4. Compliant with and able to tolerate high compression bandaging

          5. VLU present for &gt; 30 days prior to study entry

          6. VLU is full thickness

          7. The subject is willing and able to give informed consent

        Exclusion Criteria:

          1. Decrease or increase in the ulcer surface area by more than 40% during the 14 day
             run-in period

          2. More than 75% of the VLU is on or below the malleolus

          3. Presence of a non-study ulcer within 1.5 cm of the VLU

          4. A VLU which shows signs of clinical infection or has cellulitis

          5. The VLU wound bed has exposed bone, tendon or fascia

          6. BMI &gt; 45.0 kg/m2

          7. Subject is not ambulatory

          8. Subjects who have a past or present disease that, which as judged by the Investigator,
             may affect the safety of the subject or the outcome of the study

          9. Cancerous cells in the VLU

         10. HbA1c &gt;10%

         11. Blood biochemistry &gt;3x upper limit of normal

         12. Heart failure NYHA class III or IV

         13. Subjects on renal replacement therapy

         14. Immunocompromized subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Serena, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn North Centers For Advanced Wound Care, PA, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Associated Foot and Ankle Specialists, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aung Foot Health Clinics</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Arizona Limb Salvage Alliance</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Foot Care</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetic Foot &amp; Wound Treatment Center</name>
      <address>
        <city>El Centro</city>
        <state>California</state>
        <zip>92243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Foot Care and Clinical Research Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctor's Research Network</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Wound Care Group</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Passavant Area Hospital</name>
      <address>
        <city>Jacksonville</city>
        <state>Illinois</state>
        <zip>62650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Foot &amp; Ankle Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oceana Country Foot and Ankle</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08753</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's - Roosevelt Hospital Center Department of Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stonybrook Univeristy Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Wound Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn North Center For Advanced Wound Care</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16544</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn North Center For Advanced Wound Care</name>
      <address>
        <city>Kittaning</city>
        <state>Pennsylvania</state>
        <zip>16544</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center For Advanced Wound Care</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Paul's Women's Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRMC Wound Clinic</name>
      <address>
        <city>St. Geroge</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Sydney Vascular Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2228</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heidelberg Repatriation Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Awhinatina Health</name>
      <address>
        <city>Manukau</city>
        <state>Auckland</state>
        <zip>2110</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <state>Otago</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr D. Lakha</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1829</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josha Research</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boland Ethical Research Group</name>
      <address>
        <city>Cape Town</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Randles Road Medical Centre</name>
      <address>
        <city>Durban</city>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unitas Hospital</name>
      <address>
        <city>Johannesburg</city>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WorthwhileClinical Trials</name>
      <address>
        <city>Johannesburg</city>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunninghill Hospital</name>
      <address>
        <city>Johannesburg</city>
        <zip>2157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Witwatersrand University Medical School</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GCT Mercantile Clinical Trial Centre</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6020</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>April 29, 2014</last_update_submitted>
  <last_update_submitted_qc>April 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VLU</keyword>
  <keyword>Venous Leg Ulcers</keyword>
  <keyword>Ulcers</keyword>
  <keyword>chronic wounds</keyword>
  <keyword>wounds</keyword>
  <keyword>Nexagon</keyword>
  <keyword>CoDa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

